AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Read original at benzingaStocks · News reference
Amgen Identifies Unauthorized Activity In Third-party Cloud Environments In July 2026; Reports No Impact To Products, Operations, Or Financial Reporting From Incident; Reports Exfiltration Of Proprietary And Patient Data From Cloud Environments
In July 2026, Amgen Inc. (the "Company") identified unauthorized activity involving data stored in cloud environments hosted by third-party cloud service providers. Upon detecting the activity, the Company
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 31, 2026, 8:06 PM
- Checked
- Jul 31, 2026, 8:06 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of
Read original at benzingaAmgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of
Read original at benzingaAI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players
Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.
Read original at globenewswire-inc